# Lyka Labs (NSE: LYKALABS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LYKALABS · Pivot · prices to 21 Oct 2026

Lyka Labs (NSE: LYKALABS) closed at ₹84.32 on 21 Oct 2026. With a market capitalisation of ₹311 Cr, it ranks 2036th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was −10.9% in FY26. Over the past year the share price has fallen 9.0%. Its 52-week range is ₹44.10 (30 Mar 2026) to ₹98.90 (24 Oct 2025); the last close is 14.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹28 Cr (−16.2% year on year) and net profit −₹8 Cr (−497.5%), on a consolidated basis. Promoters held 58.45% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹84.32 |
| Market cap | ₹311 Cr |
| ROE | −10.9% (FY26) |
| ROCE | −7.0% (FY26) |
| Debt to equity | 0.52 |
| 52-week high | ₹98.90 (24 Oct 2025) |
| 52-week low | ₹44.10 (30 Mar 2026) |
| 1-year return | −9.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹28 Cr | −16.2% | −₹8 Cr | −497.5% | −₹2.13 |
| Q3 FY26 | ₹31 Cr | −9.1% | −₹0 Cr | −105.6% | −₹0.04 |
| Q2 FY26 | ₹37 Cr | −10.9% | −₹3 Cr | −268.1% | −₹0.94 |
| Q1 FY26 | ₹33 Cr | +9.7% | ₹1 Cr | −22.5% | ₹0.25 |
| Q4 FY25 | ₹33 Cr | +20.4% | ₹2 Cr | — | ₹0.49 |
| Q3 FY25 | ₹34 Cr | +3.8% | ₹3 Cr | +34.3% | ₹0.75 |
| Q2 FY25 | ₹41 Cr | +47.1% | ₹2 Cr | — | ₹0.58 |
| Q1 FY25 | ₹30 Cr | +31.6% | ₹1 Cr | — | ₹0.40 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹139 Cr | ₹8 Cr |
| FY24 | ₹111 Cr | −₹3 Cr |
| FY23 | ₹93 Cr | −₹13 Cr |
| FY22 | ₹194 Cr | ₹38 Cr |
| FY21 | ₹86 Cr | −₹10 Cr |
| FY20 | ₹61 Cr | −₹63 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 58.45%
- Foreign institutions: 0.17%
- Domestic institutions: 0.66%
- Non-institutions: 40.72%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |
| [Aarey Drugs & Pharmaceuticals](https://app.pivotnow.in/stock/AAREYDRUGS) | ₹114.47 | ₹325 Cr | 82.4 | — |
| [Nureca](https://app.pivotnow.in/stock/NURECA) | ₹317.10 | ₹303 Cr | 149.6 | — |
| [Ambalal Sarabhai Enterprises](https://app.pivotnow.in/stock/AMBALALSA) | ₹38.95 | ₹298 Cr | 16.8 | — |
| [Bijoy Hans](https://app.pivotnow.in/stock/BIJHANS) | — | ₹292 Cr | — | — |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |

## Questions and answers

### What is the share price of Lyka Labs today?

Lyka Labs (NSE: LYKALABS) last closed at ₹84.32 on 21 Oct 2026. Its 52-week high is ₹98.90 and its 52-week low is ₹44.10.

### What is the market cap of Lyka Labs?

Lyka Labs' market capitalisation is ₹311 Cr (₹311 Cr) at the 19 Oct 2026 close, ranking 2036th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Lyka Labs?

Return on equity was −10.9% in FY26 and return on capital employed was −7.0% in FY26 (consolidated figures).

### Is Lyka Labs a debt-free company?

No. Lyka Labs' debt-to-equity ratio was 0.52 in FY26, with total debt of ₹23 Cr.

### What were Lyka Labs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Lyka Labs reported revenue of ₹28 Cr, −16.2% year on year, and net profit of −₹8 Cr, −497.5% year on year.

### How has Lyka Labs stock performed over the last year?

Lyka Labs' share price has fallen 9.0% over the past year, +25.6% over three months and +5.3% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Lyka Labs?

As of 30 Jun 2026: promoters 58.45%, foreign institutions 0.17%, domestic institutions 0.66%, non-institutions 40.72%.

### Who are Lyka Labs' competitors?

The listed Pharma & Healthcare companies closest to Lyka Labs by market cap are Astal  Lab, Aarey Drugs & Pharmaceuticals, Nureca, Ambalal Sarabhai Enterprises, Bijoy Hans and Astonea Labs.

### Is Lyka Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Lyka Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LYKALABS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.